Sonia Quaratino

Dr Quaratino is an R&D executive with over 20 years’ experience in clinical development and immunology research. She is Chief Medical Officer at Kymab, a clinical-stage biopharmaceutical company. She is also the Chair of the Scientific and Clinical Advisory Board for STipe Therapeutics. Prior to Kymab, Dr Quaratino held a position as Global Clinical Program Leader – Translational Clinical Oncology at Novartis, responsible for the clinical development of proprietary therapeutic antibody programs in immuno-oncology. Prior to Novartis, Dr Quaratino was Senior Medical Director and Immunology Advisor at Merck Serono, where she was responsible for the clinical development of various immunomodulators. Dr Quaratino is an Italian citizen and has an extensive professional background which includes a Medical Degree and a Doctorate in Hematology-Oncology from the University of Palermo, Italy and a PhD in Immunology from Imperial College London, UK. She was also Professor of Immunology at the University of Southampton, a leading institution for innovative research. Her research group focused on the pathogenic mechanisms underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.